Interne link ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10 oktober 15, 2019 om 08:08 PM UTC
Interne link ProQR annonce des premiers résultats positifs pour l'essai de phase 1/2 du sepofarsen chez des patients souffrant d'ACL10 oktober 11, 2019 om 10:02 AM UTC
Interne link ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients oktober 10, 2019 om 10:00 AM UTC
Interne link ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO oktober 07, 2019 om 11:00 AM UTC
Interne link ProQR to Present at Two Investor Conferences in October september 30, 2019 om 11:00 AM UTC
Interne link ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa september 09, 2019 om 11:00 AM UTC
Interne link ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) augustus 12, 2019 om 11:00 AM UTC
Interne link ProQR Announces Financial Results for the Second Quarter of 2019 augustus 07, 2019 om 11:00 AM UTC
Interne link L’Agence européenne des médicaments accorde l’accès PRIME au Sepofarsen de ProQR pour l’amaurose congénitale de Leber 10 juli 29, 2019 om 04:37 PM UTC
Interne link European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10 juli 29, 2019 om 11:00 AM UTC
Interne link ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July juli 02, 2019 om 11:00 AM UTC
Interne link ProQR to Present at the JMP Securities Life Sciences Conference juni 03, 2019 om 11:00 AM UTC
Interne link ProQR to Present at the RBC Capital Markets Healthcare Conference mei 15, 2019 om 11:00 AM UTC
Interne link ProQR Announces Financial Results for the First Quarter of 2019 mei 08, 2019 om 11:00 AM UTC
Interne link ProQR to Present at Three Scientific Conferences in April april 22, 2019 om 11:00 AM UTC
Interne link ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board april 18, 2019 om 11:00 AM UTC
Interne link ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 april 15, 2019 om 11:00 AM UTC
Interne link ProQR to Present at the H.C. Wainwright Global Life Sciences Conference april 01, 2019 om 11:00 AM UTC
Interne link ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership maart 26, 2019 om 08:01 PM UTC
Interne link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2 maart 11, 2019 om 04:45 PM UTC
Interne link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2 maart 11, 2019 om 12:00 PM UTC
Interne link ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results februari 27, 2019 om 12:00 PM UTC
Interne link ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day januari 29, 2019 om 01:30 PM UTC